IBI351

· Innovent Biologics (Suzhou) Co. Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IBI351, covering 2025-01-27 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation [Phase 2]